Catalyst biosciences, inc. (CBIO)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Operating Activities
Net loss

-4,053

-13,610

-12,706

-13,779

-15,083

-10,837

-7,694

-6,482

-5,042

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-4,138

-3,750

-4,771

-4,832

-3,592

-5,130

-5,050

-1,724

-2,858

21,381

-24,185

11,189

-14,999

23,372

-12,902

-12,371

-8,066

-15,870

-7,879

14,492

2,259

-9,805

-9,054

-2,257

12,587

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

805

671

801

903

829

740

710

550

606

307

325

111

120

130

187

165

153

191

52

39

44

-2,372

2,484

-692

825

-3,859

1,291

1,252

1,614

1,378

1,440

3,112

1,916

2,002

2,148

2,200

2,163

Recognition of deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

87

-

0

0

3,536

590

768

33,645

22,857

18,945

18,756

20,744

38,994

Amortization of premium on marketable securities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

225

-

150

304

226

207

253

238

239

270

335

169

137

Depreciation and amortization

25

34

33

34

45

43

36

37

33

41

41

43

48

61

108

115

105

105

107

145

113

393

-153

370

69

452

139

170

213

400

550

630

632

626

619

635

600

Loss on disposal of property and equipment

-

-

-

-

-

0

0

0

-116

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on extinguishment of redeemable convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

7

3

4

85

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

504

-517

-78

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

21

99

62

875

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-13,634

-

-

-

-

-

-

-

-

-

-

-

-

-70

-361

14

-44

-156

243

-295

287

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid and other current assets

-1,880

13

116

457

-96

466

960

1,062

407

440

13

-381

279

-472

-54

-149

-281

1,294

259

-450

247

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-2,963

2,156

1,730

111

-966

878

235

-1,303

690

-713

959

-398

62

308

-297

109

-222

270

-5,835

724

568

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation and other accrued liabilities

866

2,655

1,141

1,703

100

616

627

832

-1,225

673

-120

760

-26

67

196

118

-441

121

525

41

463

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability and right-of-use asset

16

18

17

19

21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-15,000

-

-

-

-

0

0

0

-6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-15

-24

-15

-128

11

10

11

8

5

6

5

3

-59

-8

0

26

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

278

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash flows used in operating activities

-4,790

-8,089

-9,100

-11,466

-14,958

-9,011

-7,022

-7,413

-5,107

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,415

-9,320

-

-10,403

-17,335

-24,900

-20,529

-18,081

-23,063

-22,045

Investing Activities
Current receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

64

-

-

-

-

-

-

-

-

-

-

-

-

Other current receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-997

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-135

-

-540

271

141

-

-

-

-

-

-

-

-

Receivables from collaborations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

28

101

-

79

19

-311

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-525

-126

-1,036

702

-584

1,010

-685

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,098

-

2,023

226

-627

1,532

-2,323

-2,450

-8,274

2,118

3,872

-2,037

466

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-71

-71

-109

-111

-109

-109

-109

-859

-672

-460

742

-742

148

-

-

-

-

0

0

190

250

-

-

-

-

Net cash flows used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-4,292

-4,977

-5,109

-3,642

-4,744

-5,142

-9,629

-1,367

-2,980

25,041

-27,731

11,146

-14,846

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of short-term investments

33,457

23,466

44,962

40,731

48,274

67,630

29,644

16,756

13,937

7,500

0

-1

6,801

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of short-term investments

6,019

23,027

30,333

37,021

39,596

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of investments

-

-

-

-

-

-

-

-

12,936

-

-

-

-

-3

-5

9,727

3,682

-

-

-

-

-

-

-

7,146

-

11,077

16,685

19,242

15,809

28,639

34,608

41,916

40,714

35,091

51,244

29,204

Change in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

0

68

0

57

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of investments in marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,069

-

18,463

20,484

16,459

-

-

-

-

-

-

-

-

Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

69

-69

86

12

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of investments in marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-35,159

-48,754

-

-16,259

-20,720

-24,263

Purchases of property and equipment

17

-1

1

49

15

175

0

3

198

20

0

0

3

122

22

235

89

-

-

-

-

-

-

-

-

-50

0

22

70

195

1

91

46

252

167

414

598

Net cash flows provided by investing activities

27,421

440

14,628

3,661

8,663

4,155

-3,638

-72,641

803

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,777

-2,853

-

16,736

460

6,792

-2,191

-18,999

-30,938

-5,539

Financing Activities
Issuance of common stock for public offering, net of issuance costs

32,025

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash flows provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

6,798

5,841

2,383

-5,760

-3,772

10,975

26,439

-278

221

-19,505

19,505

-1,837

1,935

-

-

-

-

-

-

-

-

-

-

-

-

Release of restricted cash due to conversion and redemption of redeemable convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

10,255

676

592

2,807

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments for the redemption of redeemable convertible notes

-

-

-

-

-

0

0

0

5,082

403

282

6,881

6,752

10,265

676

592

2,807

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock for secondary public offering, net of issuance costs

-

-

-

-

-

0

0

1

106,761

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock from stock grants and option exercises

339

0

92

129

106

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments on long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

218

-

214

211

211

208

239

238

555

562

558

424

420

Excess tax benefits from stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,412

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net of issuance costs

-

-

-

-

-

-

-

-

-

0

0

3,554

1,782

-

-

-

-

-

-

-

-

-

276

-253

273

-

54

47

5

13

463

90

48

24

37

81,598

987

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

3,999

-11

3,271

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

13

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

-

-

-

-

-

0

0

0

9,545

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash flow provided by financing activities

32,364

0

92

129

106

71

0

37

111,224

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-164

-206

-

224

-148

-507

-538

-521

83,306

567

Net cash flow provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-4,970

-

-

-

-

167

3,980

1,882

3,284

1,956

-1,953

1,536

3,467

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

54,995

-7,649

5,620

-7,676

-6,189

-4,785

-10,660

-80,017

106,920

3,104

-21,685

10,992

-2,464

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

947

-2,016

-9,247

-8,516

6,000

20,790

237

525

7,493

-10,179

10,845

-9,444

19,927

-1,320

-6,802

-12,379

4,038

6,557

-17,023

-18,615

-23,258

-37,601

29,305

-27,017

Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Adoption of ASC 606

-

-

-

-

-

0

0

0

207

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of redeemable convertible notes to common stock

-

-

-

-

-

0

0

0

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on investments

-

-

-

-

-

-

-28

0

4

0

0

2

-1

-

-

-

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use asset and operating lease liability recorded upon the adoption of ASC 842, net

-

0

0

0

2,052

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-